Unregulated psychoactive products are arriving in dental operatories with little warning
Convenience-store and smoke-shop products marketed as “gas station medications” are creating a new kind of medication-history problem for dental teams. Tianeptine, kratom, and synthetic cannabinoids such as Delta 8 and Delta 10 sit outside the usual pharmacy channels, yet they can behave like centrally acting drugs with real physiologic consequences. In a dental setting, the concern is not abstract. Sedation planning, airway vigilance, analgesic choice, and emergency preparedness all become more complicated when a patient is taking an unreported substance that acts on opioid, stimulant, or cannabinoid pathways.
Tianeptine is especially troubling because its reputation does not match its pharmacology at higher doses. Sold in some settings as a mood stabilizer, it can stimulate opioid receptors at very high doses and has a high potential for addiction. A patient may not describe it as an opioid at all, which increases the odds that it will be missed during routine history-taking. When that happens, a clinician can misjudge tolerance, withdrawal risk, or the likelihood of unexpected sedation or respiratory depression.
Tianeptine can behave less like a mood aid and more like an opioid exposure
The pharmacologic profile of tianeptine makes it a dangerous blind spot. High-dose opioid receptor activity means the substance can overlap clinically with agents that depress the central nervous system, alter pain perception, and interact with sedatives or anesthetics. For dental teams, the practical risk is additive CNS depression when this exposure is combined with procedural sedation, anxiolytics, or postoperative pain medications. A patient who appears cooperative in the chair may still carry a hidden pharmacologic burden that changes the margin of safety.
This is where the medical history stops being a formality. An accurate review of substances used outside the pharmacy record becomes central to safe care. A patient may deny “drugs” while casually using something purchased at a corner store, and the difference matters when sedation is planned. Documentation also matters, because clear charting can protect both patient and clinician if an adverse event occurs and the history later becomes part of the review.
Kratom can push physiology in two directions at once
Kratom carries its own set of problems because its leaves can be ground and chewed, and the substance may act as both an opioid and a stimulant. That dual activity is exactly what makes it difficult to predict in clinical practice. A stimulant effect may increase restlessness, blood pressure, or anxiety, while opioid-like activity may change pain thresholds and blunt expected responses to sedatives or analgesics. In dentistry, those mixed effects can muddy what should otherwise be a straightforward assessment before local anesthesia or sedation.
For the dental team, the key issue is not simply whether the patient uses kratom, but how much, how often, and in combination with what else. Many patients who use nonprescription psychoactive products also use other agents with overlapping effects, creating a drug cocktail that can be invisible unless a clinician asks directly. Sedation protocols depend on predictability. When the underlying substance use pattern is unclear, predictability erodes quickly.
Synthetic cannabinoids can distort the usual assumptions about intoxication
Synthetic cannabinoids such as Delta 8 and Delta 10 also raise concern because they do not behave like standard, well-characterized prescription medications. They can present with unpredictable effects, and their presence in a patient’s history should prompt caution rather than assumptions. A clinician may not know whether the patient is currently intoxicated, using the substance regularly, or combining it with alcohol, cannabis, opioids, or other sedating agents.
Those uncertainties are especially important in dentistry because patients often receive multiple medications in a short window of time. Local anesthetics, sedatives, anxiolytics, and postoperative analgesics all sit in the same clinical space. If a patient’s baseline neurologic status is already altered by an unregulated psychoactive product, the threshold for oversedation, disorientation, or hemodynamic instability may be lower than expected.
Dental history-taking needs a direct question, not a vague assumption
The central lesson for dental practice is simple: patients may not volunteer use of these products unless they are asked in plain language. A careful history should include specific questions about substances purchased at convenience stores, smoke shops, gas stations, or online sources. Asking about “supplements” alone is not enough, and asking only about prescription medications misses the problem entirely.
Direct documentation has immediate value. A chart note stating that a patient denies substance use can be clinically important when the event history is reconstructed later, especially after an unexpected reaction during sedation or urgent care. When the dental record accurately captures denial or disclosure, it anchors the next clinician’s decisions and reduces ambiguity during follow-up.
The same approach applies to postoperative prescribing. If a patient is using tianeptine, kratom, or a synthetic cannabinoid, the response to common dental medications may not follow routine expectations. Analgesic selection, sedative dosing, and discharge counseling should be reconsidered with that possibility in mind. The safest path is not to guess at the biologic effect of an unregulated substance; it is to identify the exposure before treatment begins.
A substance history can prevent a sedation emergency
These products hide in plain sight because they are sold in ordinary retail environments, not because they are benign. Their accessibility makes them more likely to appear in everyday practice, and dentistry is a setting where even a single missed exposure can alter sedation safety. A clinician who asks specifically about tianeptine, kratom, and synthetic cannabinoids is not being redundant. The question may reveal the difference between a routine appointment and a preventable emergency.
The unresolved problem is how often these exposures are still going unrecognized in dental offices and how many adverse reactions they contribute to during sedation and analgesia. Until that is better defined, the safest clinical posture is direct questioning, precise documentation, and heightened caution whenever a patient’s medication list looks complete but their physiologic response does not.